Teresa Wolska-Smoleń

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Marek Hus, Anna Dmoszyńska, Maria Soroka‐Wojtaszko et al. · PubMed · 2001 · 85 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis

Tomasz Sacha, Andreas Hochhaus, Benjamin Hanfstein et al. · Leukemia Research · 2003 · 18 citations · Full text

Medicine, Hematology, Molecular Biology +13

The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group

Anna Dmoszyńska, Adam Walter‐Croneck, Iwona Hus et al. · Leukemia Research · 2010 · 18 citations · Full text

Medicine, Hematology, Oncology +12

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

Iwona Hus, Anna Dmoszyńska, Joanna Mańko et al. · British Journal of Cancer · 2004 · 15 citations · Full text

Medicine, Hematology, Pharmacology +16